A Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus Erythematosus

This study aims to describe clinical outcomes, with focus on remission, achieved with use of anifrolumab participants with SLE on standard-of-care (as recommended by 2025 China SLE guidelines). Further, it aims to describe outcomes alongside a systematic approach to glucocorticoid (GC) tapering, in terms of effectively minimising GC use, as well as discontinuing GC use, thereby reducing GC exposure.

NCT Number	NCT07751848
Lead Sponsor	AstraZeneca
Conditions	Lupus Erythematosus, Systemic
Enrollment	417 participants
Start Date	2026-09-04
Primary Completion	2028-08-25 (estimated)
Study Completion	2028-08-25 (estimated)
Updated on ClinicalTrials.gov	2026-08-07